Research and Markets: On June 21, 2006, Bayer Completed Its Acquisition of Schering for $21.5 Billion – Industry Snapshot: How Companies Are Using M&As to Strategic Advantage

Research and Markets (http://www.researchandmarkets.com/reports/c44739) has announced the addition of Industry Snapshot: How Companies Are Using M&As to Strategic Advantage to their offering.

Merger and acquisition (M&A) activity in 2005 and the first half of 2006 broke the life science industry’s tradition of relying on the pharmaceutical and biotechnology sectors for big deals. During this period, the medical device and diagnostic sectors scored big with a handful of multibillion-dollar deals. In addition, the manufacturers of generic pharmaceuticals experienced a wave of consolidation, as did life science companies in Europe and Japan.

Get the Answers You Need to Shape Your Strategy

Big pharma companies are increasingly focusing on their core prescription drug businesses and selling off other health care lines. During the period under study, which major pharmaceutical companies were most active in divesting of OTC and other businesses to concentrate on their prescription pharmaceutical business?

Until recently, the German pharmaceutical industry largely avoided the consolidation activity that took place throughout the rest of Europe and United States over the past 20 years. However, on June 21, 2006, Bayer completed its acquisition of Schering for $21.5 billion. What are the reasons behind this changing trend and what do they signify for the future of the German, indeed European, pharmaceutical industry?

In January 2006, the largest life sciences merger of the past two years was completed when Boston Scientific agreed to pay $27.2 billion for Guidant. Why are investors second-guessing Boston Scientific’s acquisition?

Thermo Electron’s anticipated acquisition of Fisher Scientifi c for $10.6 billion will form the largest single-source supplier of diagnostic equipment and services worldwide and is expected to precipitate further consolidation among other major players in the diagnostic market. How will this merger benefi t both companies?

Scope

The top deals: Boston Scientifi c’s acquisition of Guidant and Bayer’s acquisition of Schering.

Deals by industry segment: big pharma, big biotech, generics makers, and diagnostics.

Deals by geography: M&A activity in Europe and Japan.

Other deal types: technology acquisitions, acquisitions of business units/divisions, product/patent/royalty buyouts, and facility/capacity buyouts.

Content Outline:

Executive Summary

Strategic Considerations

Stakeholder Implications

Introduction

Sizable Deals/Bidding Wars

Bayer Acquires Schering

Boston Scientific Acquires Guidant

Deals by Industry Segment

Big Pharma

Diagnostics

Siemens

Inverness Medical Innovations

Thermo Electron

Generics

Big Biotech

Deals by Geography

European M&A Activity of Note

AstraZeneca

Novartis

Other European Activities

Japanese M&A Activity of Note

Other Deal Types

Technology Acquisitions of Note

Monoclonal Antibodies

Glycoengineering

Acquisitions of Business Units/Divisions

Reckitt Benckiser

Altana Pharma

Product/Patent/Royalty Buyouts

Bayer

Medtronic

Facility/Capacity Acquisitions

Novartis

Genentech

Outlook

Big Pharma

Diagnostics

Big Biotech

Europe

Japan

Tables

Figures

Companies Mentioned:

Abbott Laboratories

Abgenix

Acon Laboratories

Actavis

Alliance Boots

Altana Pharma

Amgen

Astellas Pharma

AstraZeneca

Barr Pharmaceuticals

Bayer

Bayer-Schering

Pharmaceuticals

Bayer Diagnostics

Bayer HealthCare

Biogen Idec

Bone Care International

Boots Healthcare

International

Boston Scientifi c

Bristol-Myers Squibb

Cambridge Antibody

Technology

Chiron

Daiichi Pharmaceutical

Dainippon Pharmaceutical

Dainippon Sumitomo

Pharmaceutical

Diagnostic Products

Corporation

Eon Labs

Fisher Scientifi c

Fujisawa Pharmaceutical

Genentech

Genzyme

GlaxoSmithKline

GlycArt Biotechnology

GlycoFi

Guidant

Hexal

ID Biomedical

Inverness Medical

Innovations

Ischemia Technologies

Ivax

Johnson & Johnson

Karlin Technology

KuDos Pharmaceuticals

Medtronic

Merck & Co.

Merck KGaA

NeuTec Pharma

Novartis

Nycomed

Pfi zer

PharmaDerm

Pliva

Procter & Gamble

Ranbaxy Laboratories

Reckitt Benckiser

Roche

Sankyo

Sanofi -Aventis

Schering

Siemens

Sumitomo Pharmaceutical

Syrrx

Takeda Pharmaceutical

Teva Pharmaceutical

Thermo Electron

Vicuron Pharmaceuticals

Watson Pharmaceuticals

Wyeth

Yamanouchi

Pharmaceutical

For more information visit http://www.researchandmarkets.com/reports/c44739

Source: Decision Resources